Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal
expansions of differentiated somatotroph cells and are usually sporadic. They are almost …

Guidelines and consensus statements ensure that physicians managing acromegaly
patients have access to current information on evidence-based treatments to optimize …

Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that
exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its …

Abstract Purpose The phase 3 CHIASMA OPTIMAL trial (NCT03252353) evaluated efficacy
and safety of oral octreotide capsules (OOCs) in patients with acromegaly who previously …

Acromegaly is caused by excess growth hormone (GH) secretion emanating from a
somatotroph adenoma. High GH and Insulin-like growth factor-1 (IGF-1) levels lead to acral …

Context Acromegaly, characterized by excessive GH and insulin-like growth factor-1 (IGF-1),
impacts quality of life (QoL) and mortality. Standard of care (SoC; octreotide long-acting …

Background Whereas biochemical response is often used as a primary study outcome,
improvement in symptoms and health-related quality of life (HRQoL) is the relevant goal for …

Akromegalia jest rzadką chorobą spowodowaną nadmiernym wydzielaniem hormonu
wzrostu (GH), zwykle przez guz przysadki. Rozpoznanie jest zwykle stawiane z …

Context Pasireotide long-acting release (LAR) is a somatostatin multireceptor ligand, and in
the current consensus criteria pasireotide LAR is considered the second-line medical …

Publisher Summary Acromegaly, a spectacular clinical syndrome of disordered somatic
growth and proportion, has intrigued physicians since earliest recorded history. It was …